Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2012

01.12.2012

Immunological Orchestration of Liver Fibrosis

verfasst von: Hajime Tanaka, Patrick S. C. Leung, Tom P. Kenny, M. Eric Gershwin, Christopher L. Bowlus

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Fibrosis represents the main pathophysiological consequence of all chronic inflammatory liver diseases and ultimately leads to the life-threatening clinical consequences of cirrhosis. Regardless of the underlying etiology, fibrosis involves interplay between cells of the immune systems and the direct mediators of fibrosis, including hepatic stellate cells. However, the precise physiological mechanism of liver fibrosis remains largely on enigma. Primary biliary cirrhosis (PBC) is a unique chronic, fibrosing liver disease affecting predominantly women and characterized by an immune-mediated specific destruction of the small intrahepatic bile ducts. The presence of highly specific anti-mitochondrial autoantibodies (AMA) as well as T cell responses directed agonist the pyruvate dehydrogenase E2 complex (PDC-E2) provides a unique opportunity to assess the interaction between specific immune responses and fibrogenesis. In addition, mouse models of PBC have been developed allowing the dissection of mechanisms involved in breakdown of immune tolerance, bile duct injury, and fibrosis. Recently, we reported that liver fibrosis could be induced in a xenobiotic-induced murine model of PBC by polyinosinic–polycytidylic acid (poly I:C) treatment as well as with the administration of α-galactosylceramide (α-GalCer). The aim of this article is to provide a current perspective of the immunological mechanisms that are significant in the fibrogenic processes, and potentially, for its regression by comparing PBC with other chronic inflammatory liver diseases.
Literatur
1.
van Rooij E, Olson EN (2009) Searching for miR-acles in cardiac fibrosis. Circ Res 104:138–140PubMedCrossRef
2.
Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69:213–217PubMedCrossRef
3.
Miniño AM, Murphy SL, Xu J, Kochanek K (2011) Deaths: final data for 2008. Natl Vital Stat Rep 59:1–152PubMed
4.
Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539–548PubMedCrossRef
5.
Fallowfield JA, Iredale JP (2004) Targeted treatments for cirrhosis. Expert Opin Ther Targets 8:423–435PubMedCrossRef
6.
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218PubMed
7.
Friedman SL, Rockey DC, Bissell DM (2007) Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 45:242–249PubMedCrossRef
8.
Pinzani M, Rombouts K (2004) Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 36:231–242PubMedCrossRef
9.
Tsukada S, Parsons CJ, Rippe RA (2006) Mechanisms of liver fibrosis. Clin Chim Acta 364:33–60PubMedCrossRef
10.
Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604PubMedCrossRef
11.
Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777–785PubMedCrossRef
12.
Weng HL, Liu Y, Chen JL et al (2009) The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 50:230–243PubMedCrossRef
13.
14.
Lemmers A, Moreno C, Gustot T et al (2009) The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49:646–657PubMedCrossRef
15.
Zhao L, Tang Y, You Z et al (2011) Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One 6:e18909PubMedCrossRef
16.
Wang L, Chen S, Xu K (2011) IL-17 expression is correlated with hepatitis B related liver diseases and fibrosis. Int J Mol Med 27:385–392PubMed
17.
Basha HI, Subramanian V, Seetharam A et al (2011) Characterization of HCV-specific CD4 + Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. Am J Transplant 11:775–785PubMedCrossRef
18.
Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435–452PubMedCrossRef
19.
Melhem A, Muhanna N, Bishara A et al (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45:60–71PubMedCrossRef
20.
Mehal WZ (2006) Activation-induced cell death of hepatic stellate cells by the innate immune system. Gastroenterology 130:600–603PubMedCrossRef
21.
Park O, Jeong W-IL, Wang L et al (2009) Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49:1683–1694PubMedCrossRef
22.
Seki E, De Minicis S, Osterreicher CH et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324–1332PubMedCrossRef
23.
Seki E, Park E, Fujimoto J (2011) Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. Hepatol Res 41:597–610PubMedCrossRef
24.
Friedman SL, Roll FJ, Boyles J, Bissell DM (1985) Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 82:8681–8685PubMedCrossRef
25.
Otto DA, Veech RL (1980) Isolation of a lipocyte-rich fraction from rat liver nonparenchymal cells. Adv Exp Med Biol 132:509–517PubMed
26.
Maher JJ, Bissell DM, Friedman SL, Roll FJ (1988) Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest 82:450–459PubMedCrossRef
27.
Milani S, Herbst H, Schuppan D, Kim KY, Riecken EO, Stein H (1990) Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 98:175–184PubMed
28.
Marra F (1999) Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31:1120–1130PubMedCrossRef
29.
Iredale JP (2001) Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 21:427–436PubMedCrossRef
30.
Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21:311–335PubMedCrossRef
31.
Rockey DC (2001) Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 21:337–349PubMedCrossRef
32.
Olaso E, Salado C, Egilegor E et al (2003) Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37:674–685PubMedCrossRef
33.
Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275:2247–2250PubMedCrossRef
34.
Bataller R, Gines P, Nicolas JM et al (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118:1149–1156PubMedCrossRef
35.
Rockey DC (2001) Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liver Dis 5:851–865PubMedCrossRef
36.
Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425–456PubMedCrossRef
37.
Duffield JS, Forbes SJ, Constandinou CM et al (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65PubMed
38.
Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H (2005) Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 128:138–146PubMedCrossRef
39.
Matsuoka M, Tsukamoto H (1990) Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 11:599–605PubMedCrossRef
40.
Pinzani M (2002) PDGF and signal transduction in hepatic stellate cells. Front Biosci 7:d1720–d1726PubMedCrossRef
41.
Bissell DM, Roulot D, George J (2001) Transforming growth factor beta and the liver. Hepatology 34:859–867PubMedCrossRef
42.
Tiggelman AM, Boers W, Linthorst C, Sala M, Chamuleau RA (1995) Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of IL-1 beta, IL-4, TGF beta and IFN gamma. J Hepatol 23:307–317PubMed
43.
Shi Z, Wakil AE, Rockey DC (1997) Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 94:10663–10668PubMedCrossRef
44.
Wynn TA, Cheever AW, Jankovic D et al (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594–596PubMedCrossRef
45.
Granstein RD, Murphy GF, Margolis RJ, Byrne MH, Amento EP (1987) Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 79:1254–1258PubMedCrossRef
46.
Mentink-Kane MM, Cheever AW, Wilson MS et al (2011) Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Rα2. Gastroenterology 141:2200–2209PubMedCrossRef
47.
Hoffmann KF, Cheever AW, Wynn TA (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 164:6406–6416PubMed
48.
Liang SC, Tan XY, Luxenberg DP et al (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271–2279PubMedCrossRef
49.
Lan RY, Salunga TL, Tsuneyama K et al (2009) Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 32:43–51PubMedCrossRef
50.
Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864–871PubMedCrossRef
51.
Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMed
52.
Wolk K, Witte E, Witte K, Warszawska K, Sabat R (2010) Biology of interleukin-22. Semin Immunopathol 32:17–31PubMedCrossRef
53.
Aujla SJ, Kolls JK (2009) IL-22: a critical mediator in mucosal host defense. J Mol Med (Berl) 87:451–454CrossRef
54.
Radaeva S, Sun R, Pan HN, Hong F, Gao B (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39:1332–1342PubMedCrossRef
55.
Pan H, Hong F, Radaeva S, Gao B (2004) Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1:43–49PubMed
56.
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA (2007) Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27:647–659PubMedCrossRef
57.
Ki SH, Park O, Zheng M et al (2010) Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52:1291–1300PubMedCrossRef
58.
Xiang X, Gui H, King NJ et al (2011) IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol. doi:10.​1038/​icb.​2011.​79
59.
Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 86:513–528PubMed
60.
Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 97:5498–5503PubMedCrossRef
61.
Dong Z, Zhang J, Sun R, Wei H, Tian Z (2007) Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice. Hepatology 45:1400–1412PubMedCrossRef
62.
Ito H, Ando K, Nakayama T et al (2003) Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo. Hepatology 38:1116–1124PubMedCrossRef
63.
Nakashima H, Inui T, Habu Y et al (2006) Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy. Gastroenterology 131:1573–1583PubMedCrossRef
64.
Li B, Sun R, Wei H, Gao B, Tian Z (2006) Interleukin-15 prevents concanavalin A-induced liver injury in mice via NKT cell-dependent mechanism. Hepatology 43:1211–1219PubMedCrossRef
65.
Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87–95PubMedCrossRef
66.
Jeong WI, Park O, Radaeva S, Gao B (2006) STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44:1441–1451PubMedCrossRef
67.
Gao B, Radaeva S, Jeong W-I (2007) Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 1:173–180PubMedCrossRef
68.
Krizhanovsky V, Yon M, Dickins RA et al (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 134:657–667PubMedCrossRef
69.
Laso FJ, Madruga JI, Giron JA et al (1997) Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 25:1096–1100PubMedCrossRef
70.
Pan HN, Sun R, Jaruga B, Hong F, Kim WH, Gao B (2006) Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis. Alcohol Clin Exp Res 30:1615–1623PubMedCrossRef
71.
Szabo G, Mandrekar P (2009) A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 33:220–232PubMedCrossRef
72.
Arteel GE (2008) Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells. Gastroenterology 134:351–353PubMedCrossRef
73.
Jeong WI, Park O, Gao B (2008) Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 134:248–258PubMedCrossRef
74.
Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U (2006) Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55:869–877PubMedCrossRef
75.
Jinushi M, Takehara T, Tatsumi T et al (2004) Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173:6072–6081PubMed
76.
Morishima C, Paschal DM, Wang CC et al (2006) Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43:573–580PubMedCrossRef
77.
Yamagiwa S, Matsuda Y, Ichida T et al (2008) Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res 38:664–672PubMedCrossRef
78.
Golden-Mason L, Madrigal-Estebas L, McGrath E et al (2008) Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121–1128PubMedCrossRef
79.
Kawarabayashi N, Seki S, Hatsuse K et al (2000) Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32:962–969PubMedCrossRef
80.
Minagawa M, Deng Q, Liu ZX, Tsukamoto H, Dennert G (2004) Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126:1387–1399PubMedCrossRef
81.
de Lalla C, Galli G, Aldrighetti L et al (2004) Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 173:1417–1425PubMed
82.
Schwabe RF, Seki E, Brenner DA (2006) Toll-like receptor signaling in the liver. Gastroenterology 130:1886–1900PubMedCrossRef
83.
Seki E, Tsutsui H, Nakano H et al (2001) Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 166:2651–2657PubMed
84.
Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF (2010) Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis 30:232–244PubMedCrossRef
85.
Isayama F, Hines IN, Kremer M et al (2006) LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 290:G1318–G1328PubMedCrossRef
86.
Gao B, Jeong WI, Tian Z (2008) Liver: an organ with predominant innate immunity. Hepatology 47:729–736PubMedCrossRef
87.
Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA (2003) Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37:1043–1055PubMedCrossRef
88.
Watanabe A, Hashmi A, Gomes DA et al (2007) Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46:1509–1518PubMedCrossRef
89.
Gabele E, Muhlbauer M, Dorn C et al (2008) Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Com 376:271–276PubMedCrossRef
90.
Connolly MK, Bedrosian AS, Mallen-St Clair J et al (2009) In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 119:3213–3225PubMed
91.
Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820PubMedCrossRef
92.
Jeong WI, Park O, Suh YG et al (2011) Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 53:1342–1351PubMedCrossRef
93.
Lee RG, Epstein O, Jauregui H, Sherlock S, Scheuer PJ (1981) Granulomas in primary biliary cirrhosis: a prognostic feature. Gastroenterology 81:983–986PubMed
94.
Poynard T (2003) A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38:257–265PubMedCrossRef
95.
Ludwig J, Dickson ER, McDonald GS (1978) Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379:103–112PubMedCrossRef
96.
Scheuer P (1967) Primary biliary cirrhosis. Proc R Soc Med 60:1257–1260PubMed
97.
Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y (1995) HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181:1835–1845PubMedCrossRef
98.
Harada K, Van de Water J, Leung PS et al (1997) In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 25:791–796PubMedCrossRef
99.
Tsuneyama K, Yasoshima M, Harada K, Hiramatsu K, Gershwin ME, Nakanuma Y (1998) Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 28:620–623PubMedCrossRef
100.
Kita H, Naidenko OV, Kronenberg M et al (2002) Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031–1043PubMedCrossRef
101.
Kikuchi K, Lian ZX, Yang GX et al (2005) Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 128:304–312PubMedCrossRef
102.
Amano K, Leung PS, Rieger R et al (2005) Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol 174:5874–5883PubMed
103.
Mao TK, Lian ZX, Selmi C et al (2005) Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 42:802–808PubMedCrossRef
104.
Chuang YH, Lian ZX, Tsuneyama K et al (2006) Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 26:232–240PubMedCrossRef
105.
Lan RY, Cheng C, Lian ZX et al (2006) Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 43:729–737PubMedCrossRef
106.
Moritoki Y, Lian ZX, Wulff H et al (2007) AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 45:314–322PubMedCrossRef
107.
Lleo A, Bowlus CL, Yang GX et al (2010) Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52:987–998PubMedCrossRef
108.
Shimoda S, Harada K, Niiro H et al (2011) Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 53:1270–1281PubMedCrossRef
109.
Tsuda M, Ambrosini YM, Zhang W et al (2011) Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology 54:1293–1302PubMedCrossRef
110.
Wakabayashi K, Yoshida K, Leung PS et al (2009) Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 155:577–586PubMedCrossRef
111.
Moritoki Y, Tsuda M, Tsuneyama K et al (2011) B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis. Cell Immunol 268:16–23PubMedCrossRef
112.
Ambrosini YM, Yang GX, Zhang W et al (2011) The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 166:110–120PubMedCrossRef
113.
Wu SJ, Yang YH, Tsuneyama K et al (2011) Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 53:915–925PubMedCrossRef
114.
Dhirapong A, Lleo A, Yang GX et al (2011) B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology 53:527–535PubMedCrossRef
115.
Yang GX, Wu Y, Tsukamoto H et al (2011) CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J Immunol 186:1259–1267PubMedCrossRef
116.
Oertelt S, Lian ZX, Cheng CM et al (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 177:1655–1660PubMed
117.
Chuang YH, Lian ZX, Yang GX et al (2008) Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47:571–580PubMedCrossRef
118.
Yang GX, Lian ZX, Chuang YH et al (2008) Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 47:1974–1982PubMedCrossRef
119.
Yoshida K, Yang GX, Zhang W et al (2009) Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 50:1494–1500PubMedCrossRef
120.
Moritoki Y, Zhang W, Tsuneyama K et al (2009) B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 136:1037–1047PubMedCrossRef
121.
Zhang W, Tsuda M, Yang GX et al (2010) Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology 52:215–222PubMedCrossRef
122.
Sekiya H, Komatsu T, Isono E et al (1999) Decrease in the prevalence of IL-4-producing CD4+ T cells in patients with advanced stage of primary biliary cirrhosis. Am J Gastroenterol 94:3589–3594PubMedCrossRef
123.
Mattner J, Savage PB, Leung P et al (2008) Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3:304–315PubMedCrossRef
124.
Collison LW, Workman CJ, Kuo TT et al (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566–569PubMedCrossRef
125.
Collison LW, Vignali DA (2008) Interleukin-35: odd one out or part of the family? Immunol Rev 226:248–262PubMedCrossRef
126.
Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251–276PubMedCrossRef
127.
Oppmann B, Lesley R, Blom B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–725PubMedCrossRef
128.
Gillessen S, Carvajal D, Ling P et al (1995) Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 25:200–206PubMedCrossRef
129.
Pulickal AS, Hambleton S, Callaghan MJ et al (2008) Biliary cirrhosis in a child with inherited interleukin-12 deficiency. J Trop Pediatr 54:269–271PubMedCrossRef
130.
Hirschfield GM, Liu X, Xu C et al (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360:2544–2555PubMedCrossRef
131.
Rong G, Zhou Y, Xiong Y et al (2009) Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 156:217–225PubMedCrossRef
132.
Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y (2009) Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 157:261–270PubMedCrossRef
133.
Hammerich L, Heymann F, Tacke F (2011) Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol 2011:1–12CrossRef
134.
Harada K, Isse K, Tsuneyama K, Ohta H, Nakanuma Y (2003) Accumulating CD57 + CD3 + natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis. Liver Int 23:94–100PubMedCrossRef
135.
Takii Y, Nakamura M, Ito M et al (2005) Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 85:908–920PubMedCrossRef
136.
Muddu AK, Guha IN, Elsharkawy AM, Mann DA (2007) Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 39:695–714PubMedCrossRef
Metadaten
Titel
Immunological Orchestration of Liver Fibrosis
verfasst von
Hajime Tanaka
Patrick S. C. Leung
Tom P. Kenny
M. Eric Gershwin
Christopher L. Bowlus
Publikationsdatum
01.12.2012
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2012
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8323-1

Weitere Artikel der Ausgabe 3/2012

Clinical Reviews in Allergy & Immunology 3/2012 Zur Ausgabe

ReviewPaper

Treatment of ANCA-Associated Vasculitis, Where to Go?

ReviewPaper

To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra

ReviewPaper

Antineutrophil Cytoplasmic Autoantibodies: How Are They Detected and What Is Their Use for Diagnosis, Classification and Follow-up?

ReviewPaper

N-TproBNP as Biomarker in Systemic Sclerosis

ReviewPaper

The Long-Term Marriage Between Autoimmunity and Internal Medicine: A Homage to Manuel Carlos Dias

ReviewPaper

Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise